CoLucid Pharmaceuticals (CLCD) : Traders are bullish on CoLucid Pharmaceuticals (CLCD) as it has outperformed the S&P 500 by a wide margin of 236.2% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 28%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 28.68% in the last 1 week, and is up 229.39% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 92.85% and the 50-Day Moving Average is 152.42%.The 200 Day SMA reached 263.07% CoLucid Pharmaceuticals, Inc. is up 305.33% in the last 3-month period. Year-to-Date the stock performance stands at 236.08%.
CoLucid Pharmaceuticals (CLCD) stock is expected to deviate a maximum of $13.53 from the average target price of $32.5 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $52 and the most muted being $21.
For this week, the average consensus of the company shares are rated as a Strong Buy. CoLucid Pharmaceuticals (NASDAQ:CLCD): The stock opened at $26.77 and touched an intraday high of $28.44 on Friday. During the day, the stock corrected to an intraday low of $26.15, however, the bulls stepped in and pushed the price higher to close in the green at $28.13 with a gain of 5.28% for the day. The total traded volume for the day was 1,132,699. The stock had closed at $28.13 in the previous trading session.
CoLucid Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate, Lasmiditan, for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan, including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.